23:29 , May 3, 2019 |  BioCentury  |  Product Development

Independents’ day: after their first solo launch, biotechs look to new partnering strategies

Having taken their first products to market alone, the new class of independent biotechs face decisions for what to keep and what to change as they seek to build sustainable value as end-to-end companies. One...
17:09 , Sep 29, 2017 |  BioCentury  |  Strategy

Agios’ acceleration

A biomarker-driven strategy in a setting where response was easy to measure, along with a healthy pile of cash, allowed Agios Pharmaceuticals Inc. to go from concept to marketed drug in just over eight years....
00:49 , Dec 20, 2016 |  BC Week In Review  |  Clinical News

Agios discontinues development of AG-519 to treat pyruvate kinase deficiency

Agios said it discontinued development of AG-519 to treat pyruvate kinase deficiency after FDA placed a clinical hold on the candidate. On a conference call, the company said the hold was linked to a treatment-related...
23:23 , Dec 16, 2016 |  BC Extra  |  Company News

Agios sags after discontinuing PKD program

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) sank $10.87 (19%) to $45.07 on Friday after discontinuing development of AG-519 to treat pyruvate kinase deficiency. The company said Thursday after market hours that FDA placed a clinical hold on...
00:01 , Dec 16, 2016 |  BC Extra  |  Clinical News

Agios discontinues PKD candidate

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) fell $10.66 (19%) to $45.28 in early after hours trading after it said it discontinued development of AG-519 to treat pyruvate kinase deficiency after FDA placed a clinical hold on the...
20:26 , Dec 9, 2016 |  BC Week In Review  |  Clinical News

AG-519: Additional Ph I data

Data from 40 healthy volunteers in the second part of a 3-part, double-blind, U.K. Phase I trial showed that twice-daily 10-375 mg doses of oral AG-519 for 14 days reduced mean blood 2,3-diphosphoglycerate (2,3-DPG) levels...
20:23 , Dec 9, 2016 |  BC Week In Review  |  Clinical News

AG-348: Additional Ph II DRIVE-PK data

Data from 32 transfusion-independent adult patients with pyruvate kinase deficiency in the open-label, international Phase II DRIVE-PK trial showed that twice-daily 50 and 300 mg oral AG-348 for up to 6 months improved hemoglobin levels...
00:48 , Dec 6, 2016 |  BC Extra  |  Clinical News

Agios posts AML data after day's slump

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) slipped $7.10 (12%) to $49.87 on Monday after reporting new data from Phase I studies of AG-519 and AG-348 , two small molecule activators of pyruvate kinase R to treat pyruvate...
00:47 , Dec 6, 2016 |  BC Extra  |  Clinical News

Agios' posts AML data after day's slump

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) slipped $7.10 (12%) to $49.87 on Monday after reporting new data from Phase I studies of AG-519 and AG-348 , two small molecule activators of pyruvate kinase R to treat pyruvate...
00:47 , Dec 6, 2016 |  BC Extra  |  Clinical News

Agios' posts AML data after day's slump

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) slipped $7.10 (12%) to $49.87 on Monday after reporting new data from Phase I studies of AG-519 and AG-348 , two small molecule activators of pyruvate kinase R to treat pyruvate...